⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SRPT News
Sarepta Therapeutics,, Inc. Common Stock
Immunoassay Market Research, Strategies, Trends and Forecasts Report 2025 with Executive Guides and Impact of Artificial Intelligence - ResearchAndMarkets.com
businesswire.com
ALGN
AMZN
BDX
BIO
BMY
CDNS
CERN
CHKP
CLVS
CODX
CRSP
CYTK
DELL
DGX
DHR
DIS
DTC
DXCM
ENZ
EXAS
FSLR
GILD
GOOG
IDXX
ILMN
INCY
INTC
ISRG
JNJ
LULU
LUMX
MDLZ
MRNA
MSFT
MYL
NBIX
NCLH
NFLX
NVS
NVTA
ORCL
ORGO
OSIP
OTIS
PANW
PFE
PG
PGR
PPC
PRGO
QCOM
QGEN
QORV
QUID
REGN
ROCH
ROST
SGEN
SIRI
SNPS
SPLK
SRPT
SWKS
SYK
TCOM
TEAM
TEVA
TGT
TMO
TSLA
TXN
ULTA
UNH
VRTX
WBA
WDC
WEC
WFC
XRAY
XTRA
ZBRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
accessnewswire.com
SRPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
accessnewswire.com
SRPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
accessnewswire.com
SRPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
accessnewswire.com
SRPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
accessnewswire.com
SRPT
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
businesswire.com
SRPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
accessnewswire.com
SRPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
accessnewswire.com
SRPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
accessnewswire.com
SRPT